



(51) International Patent Classification:

C07K 16/18 (2006.01) C07K 16/00 (2006.01)
C07K 16/14 (2006.01) C07K 16/40 (2006.01)

(21) International Application Number:

PCT/EP2024/076826

(22) International Filing Date:

25 September 2024 (25.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23199373.4 25 September 2023 (25.09.2023) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **BERTOLDO, Davide**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **BUTZER, Joachim**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **FENN, Sebastian**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **FIDLER, Alexander**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **JOCHNER, Anton**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **KOERTVELY, Eloed**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **MARY,**


Jean-Luc; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **PRINER, Sebastian**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE).

(74) Agent: **MERTES, Maria**; Nonnenwald 2, 82377 Penzberg (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODY THAT BINDS TO C3bBb



Trimeric complex: C3bBb + Fab



C3bBb complex showing the epitope of the Fab on C3b (cyan - ca. 60% of contact surface) and Bb (blue - ca. 40% of contact surface).

Fig. 1

(57) Abstract: The present invention relates to anti-C3bBb antibodies and methods of using the same.

[Continued on next page]

WO 2025/068207 A1

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*